Skip to content

Clobetasol Propionate

DRUG18 trials

Sponsors

Uniwersytet Medyczny W Lublinie, Centre Hospitalier Universitaire Amiens Picardie, Stiefel, a GSK Company, GlaxoSmithKline, Academic and Community Cancer Research United

Conditions

Alopecia AreataBullous PemphigoidBullous pemphigoidCataractCataracts InfantileColon AdenocarcinomaDermatitis, AtopicHand Dermatosis

Phase 1

Phase 2

Phase 3

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
CompletedNCT04246801
SalvatCataract
Start: 2020-06-10End: 2021-05-19Updated: 2022-12-22
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
CompletedNCT04249076
SalvatCataract
Start: 2020-06-04End: 2021-04-14Updated: 2022-12-22
Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients
NCT04649697
Cairo UniversityRheumatoid Arthritis
Start: 2020-12-01End: 2023-12-30Target: 39Updated: 2023-09-21
Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva
WithdrawnNCT05364515
Fundación Eduardo AnituaLichen Sclerosus of Vulva
Start: 2021-12-23End: 2024-02-15Updated: 2025-02-27
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
RecruitingNCT05724446
SalvatCataracts Infantile
Start: 2022-12-12End: 2025-12-31Target: 60Updated: 2024-09-27
Randomised phase III, partly blinded study comparing the efficacy and safety of clobetasol, mometasone and tacrolimus in the treatment of lichen sclerosus of the vulva in a paediatric population.
Not yet recruitingCTIS2024-514003-33-00
Uniwersytet Medyczny W LubliniePatients with clinically diagnosed lichen sclerosus of the vulva.
Target: 93Updated: 2025-08-29

Phase 4

Unknown Phase

Related Papers